These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25736944)

  • 21. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
    Trissel LA; Williams KY; Gilbert DL
    J Am Pharm Assoc (Wash); 2000; 40(4):515-9. PubMed ID: 10932461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1993 Nov; 50(11):2359-63. PubMed ID: 8266963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
    Fox LM; Wilder AG; Foushee JA
    Am J Health Syst Pharm; 2013 Mar; 70(6):520-4. PubMed ID: 23456406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs.
    Dasta JF; Hale KN; Stauffer GL; Tschampel MM
    Am J Hosp Pharm; 1988 Nov; 45(11):2361-6. PubMed ID: 3228093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.
    So W; Kim L; Thabit AK; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2017 Jan; 74(1):e55-e63. PubMed ID: 28007722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The clinical pharmacology of cisatracurium].
    Mellinghoff H; Diefenbach C
    Anaesthesist; 1997 Jun; 46(6):481-5. PubMed ID: 9297378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration.
    Karnatz NN; Wong J; Kesler H; Baaske DM; Speicher ER
    Am J Hosp Pharm; 1988 Feb; 45(2):368-71. PubMed ID: 2896460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compatibility of aminophylline and verapamil in intravenous admixtures.
    Johnson CE; Lloyd CW; Mesaros JL; Rubley GJ
    Am J Hosp Pharm; 1989 Jan; 46(1):97-100. PubMed ID: 2712035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Cisatracurium Versus Atracurium in Early ARDS.
    Moore L; Kramer CJ; Delcoix-Lopes S; Modrykamien AM
    Respir Care; 2017 Jul; 62(7):947-952. PubMed ID: 28351905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of cisatracurium and rocuronium on cisatracurium precurarization and the priming principle.
    Mak PH; Irwin MG
    J Clin Anesth; 2004 Mar; 16(2):83-7. PubMed ID: 15110367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does ester hydrolysis change the in vitro degradation rate of cisatracurium and atracurium?
    Weindlmayr-Goettel M; Gilly H; Kress HG
    Br J Anaesth; 2002 Apr; 88(4):555-62. PubMed ID: 12066733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients.
    Meeder AM; van der Steen MS; Rozendaal A; van Zanten AR
    BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27698008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection.
    Thompson DF; Stiles ML; Allen LV; Tu YH
    Am J Hosp Pharm; 1988 Jan; 45(1):142-5. PubMed ID: 3348228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Jan; 54(1):56-60. PubMed ID: 9117791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisatracurium dosing in a patient with hyperthermia.
    Lim J; Cox J; Nguyen T; Arya R
    Am J Health Syst Pharm; 2019 Jul; 76(14):1029-1032. PubMed ID: 31361873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
    Chan P; Bishop A; Kupiec TC; Trissel LA; Gole D; Jimidar IM; Vermeersch H
    Am J Health Syst Pharm; 2008 Aug; 65(16):1545-51. PubMed ID: 18693210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
    Woloschuk DM; Wermeling JR; Pruemer JM
    Am J Hosp Pharm; 1991 Oct; 48(10):2158-60. PubMed ID: 1781472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.